Clinical Trial Detail

NCT ID NCT02499952
Title Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nasser Hanna, M.D.
Indications

germ cell cancer

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.